Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 149 IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 149 IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium is the major intracellular cation; it maintains cellular membrane potential, nerve impulse transmission, and muscle contraction. Sodium chloride provides sodium and chloride ions for extracellular fluid balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: Adults, 10-20 mEq/h (as potassium) via central line; rate not to exceed 10-20 mEq/h; maximum 150 mEq/day. Concentration 0.149% provides 2 mEq K+/100 mL.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Potassium has no classic terminal half-life as it is an electrolyte. In stable patients, the whole-body turnover half-life is approximately 30 minutes due to rapid distribution and renal clearance.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal: approximately 90% of potassium is excreted via the kidneys, with about 10% eliminated in feces. Renal excretion is regulated by aldosterone and distal nephron secretion.
Category C
Category A/B
Electrolyte
Electrolyte